Kezdőlap Mélykutatási eredmények QA Jelek Területek Módszertan Névjegy Keresés Rákkutatás Publikációk, biológiai célpontok, gyógyszerek, bizonyítékszintek és klinikai vizsgálatok.
A rákkutatási terület evidencialétrát használ a sejtmodelltől a klinikai gyakorlatig. A rendszer kutatási tájékozódást ad, nem diagnosztizál és nem választ kezelést.
Jelek A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions — Renal cell carcinomaClinical utility and future perspectives of liquid biopsy in colorectal cancer — Colorectal cancerChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial — Ovarian cancerThe global burden of stomach cancer and its risk factors from 1990 to 2021: findings from the Global Burden of Disease Study 2021 — Gastric cancer... — Colorectal cancerExploring the efficacy of fluorouracil and platinum based chemotherapy in advanced hepatocellular carcinoma to bridge the treatment gap in resource limited settings — Hepatocellular carcinomaTransarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial — Hepatocellular carcinomaGlioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies — MelanomaOvercoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies — Gastric cancerTargeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives — Gastric cancerImproved overall survival in an anti‑PD‑L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial — GlioblastomaNSCLC: Current Evidence on Its Pathogenesis, Integrated Treatment, and Future Perspectives — NSCLCHealth-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial — Hepatocellular carcinomaImproving immunotherapy for the treatment of hepatocellular carcinoma: learning from patients and preclinical models — Hepatocellular carcinomaTherapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson — NSCLCBevacizumab-FOLFOXIRI in First Line Treatment of BRAF V600E - Mutant Metastatic Colorectal Cancer: A Single-Center Study — Colorectal cancerHarnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations — Colorectal cancerHepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors — Hepatocellular carcinomaReal‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort — Hepatocellular carcinomaAdvances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer — Prostate cancerElőző 56/102 Következő